Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin's Disease or Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

April 30, 1996

Primary Completion Date

April 30, 2003

Study Completion Date

January 31, 2008

Conditions
Lymphoma
Interventions
DRUG

aminocamptothecin

850 micrograms/square meter/day (total dose 2550 micrograms/square meter) via central venous catheter using infusion pump over 72 hours + one cycle Cycle repeated every 14 days for minimum of 6 cycles if partial or complete response

Trial Locations (5)

55455

University of Minnesota Cancer Center, Minneapolis

63110

Washington University Barnard Cancer Center, St Louis

20307-5000

Walter Reed Army Medical Center, Washington D.C.

08103

Cooper Cancer Institute, Camden

07503

St. Joseph's Hospital and Medical Center, Paterson

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00002745 - Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin's Disease or Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter